Validation of the Barcelona Magnetic Resonance Imaging Predictive Model for Significant Prostate Cancer Detection in Men Undergoing Mapping per 0.5 Mm-Core Targeted Biopsies of Suspicious Lesions and Perilesional Areas
Authors:
Open Access
Abstract
Background/Objectives: Validation of predictive models (PMs) is crucial to be implemented in new populations or when advances in diagnostic approaches occurred. The aim of this study is to validate the BCN-MRI PM for sPCa when a highly effective prostate biopsy protocol is used. Methods: A prospective cohort of 457 men suspected of having PCa, for whom MRI results were reported with the Prostate Imaging-Reporting and Data System (PI-RADS) v 2.1, underwent a per 0.5 mm-core mapping targeted biopsy of suspicious lesions and perilesional areas, followed by a 12-core-systematic biopsy. These procedures took place between 1 February 2022, and 29 February 2024, at a reference center for prostate biopsy. The individual likelihood of sPCa was assessed through the BCN-MRI risk calculator. Results: The overall sPCa detection rate was 58.3%. The calibration curve of the BCN-MRI PM showed an appropriate accuracy between expected and observed probabilities with a discrimination ability for sPCa yielding an area under the curve (AUC) of 0.862 (95% CI 0.828–0.896) comparable to the AUC of 0.858 (95% CI 0.833–0.883) observed in the development cohort. The application of the BCN-MRI PM provided a net benefit over performing biopsies on all men, avoiding 24.9% of prostate biopsies at 95% sensitivity for sPCa, compared to the 23.7% reduction observed in the development cohort. Conclusions: We conclude that the BCN-MRI PM is ready to be implemented when this biopsy protocol is employed.Keywords
Funding Information
- Ministerio de Asuntos Económicos y Transformación Digital (SP) (MIA.2021.M02.0005, PI20/01666)
- Instituto de Salut Carlos III (SP) (MIA.2021.M02.0005, PI20/01666)
This publication has 46 references indexed in Scilit:
- Regional Versus Systematic Biopsy in Addition to Targeted Biopsy: Results from a Systematic Review and Meta-analysisEuropean Urology Oncology, 2024
- Precision matters: the value of PET/CT and PET/MRI in the clinical management of cervical cancerStrahlentherapie und Onkologie, 2024
- External validation of the barcelona magnetic resonance imaging predictive model for detecting significant prostate cancer including men receiving 5-alpha reductase inhibitorsWorld Journal of Urology, 2024
- Statistical methods for validation of predictive modelsJournal of Nuclear Cardiology, 2022
- A European Model for an Organised Risk-stratified Early Detection Programme for Prostate CancerEuropean Urology Oncology, 2021
- Nitrogen‐containing flavonoid and their analogs with diverse B‐ring in acetylcholinesterase and butyrylcholinesterase inhibitionDrug Development Research, 2020
- Structure–activity study of fluorine or chlorine‐substituted cinnamic acid derivatives with tertiary amine side chain in acetylcholinesterase and butyrylcholinesterase inhibitionDrug Development Research, 2019
- Transparent Reporting of a multivariable prediction model for Individual Prognosis Or Diagnosis (TRIPOD): the TRIPOD StatementBritish Journal of Surgery, 2015
- Evaluation of the ESUR PI-RADS scoring system for multiparametric MRI of the prostate with targeted MR/TRUS fusion-guided biopsy at 3.0 TeslaEuropean Radiology, 2013
- ESUR prostate MR guidelines 2012European Radiology, 2012